1. Pink Sheet
  2. >>Market Access
  3. >>Pricing Debate

House 340B Reform Bill Would Require Discount Pass Through, Define Patient, Hospital Eligibility

 
• By Cathy Kelly

Legislation is the fruit of PhRMA’s lobbying collaboration with the National Association of Community Health Centers. It would also require manufacturers to supply contract pharmacies, within limits.

'ASAP 340B' Is PhRMA/NACHC Lobbying Initiative • Source: Shutterstock

Hospitals benefitting from the 340B outpatient drug discount program would be required to pass through manufacturer discounts to certain low-income patients under a new bill introduced by Reps. Larry Bucshon, R-IN; Buddy Carter, R-GA; and Diana Harshbarger, R-TN, on 28 May.

Key Takeaways

  • House Republican bill including a broad range of 340B reform policies supported by manufacturers was introduced 28 May.

  • The bill would require hospitals to pass through manufacturer discounts to low income patients and set eligibility requirements for patients and hospitals benefitting from the outpatient discount program, among other provisions

Currently, the 340B program “has no such patient affordability requirements for medicines, and evidence suggests that only a small share of 340B hospitals use some of their 340B margin to help

More from Pricing Debate

Industry Leaders Grapple With Trump’s Most Favored Nation Pricing Plan

 
• By Jessica Merrill

At the Bank of America health care conference, pharma leaders speculated on the impact of Trump’s most favored nation pricing executive order on US and European markets.

Most Favored Nation Policy ‘Lazy, Misguided,’ But US Price Reforms Politically ‘Inevitable’

 
• By Cathy Kelly

Policy experts and pharma executives react to President Trump’s executive order on “equalizing” drug prices between the US and comparable nations at the ISPOR 2025 conference.

New Guidance Suggests SubQ Keytruda, Opdivo Formulations May Not Avoid Medicare Negotiations

 
• By Sarah Karlin-Smith

New draft guidance on the third cycle of Medicare drug price negotiations goes against Merck and BMS expectations for their cancer drugs. The guidance also tackles Part B and renegotiated prices for the first time.

House Budget Bill Includes Delayed Orphan Fix, Also Risks Downstream Cell and Gene Coverage

 
• By Sarah Karlin-Smith

The first two classes of negotiated drugs under the Inflation Reduction Act would not benefit from a rare disease adjustment House Republicans included in their reconciliation package.

More from Market Access

New Guidance Suggests SubQ Keytruda, Opdivo Formulations May Not Avoid Medicare Negotiations

 
• By Sarah Karlin-Smith

New draft guidance on the third cycle of Medicare drug price negotiations goes against Merck and BMS expectations for their cancer drugs. The guidance also tackles Part B and renegotiated prices for the first time.

Industry On Making England’s HTA Innovation Lab A Success

 
• By Eliza Slawther

England’s health technology assessment institute, NICE, must ensure that there is clarity for manufacturers on how its methods and processes might change following testing in its sandbox environment, the Association of the British Pharmaceutical Industry said.

House Budget Bill Includes Delayed Orphan Fix, Also Risks Downstream Cell and Gene Coverage

 
• By Sarah Karlin-Smith

The first two classes of negotiated drugs under the Inflation Reduction Act would not benefit from a rare disease adjustment House Republicans included in their reconciliation package.